Trial Profile
Phase I Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2020
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 12 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 02 Jan 2019 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 02 Jan 2019 Planned primary completion date changed from 1 May 2018 to 1 May 2019.